Household & Personal Products

Unilever PLC prepares a Rule 425 disclosure on its proposed merger with McCormick & Company, outlining strategic synergies, regulatory risks, and potential long‑term shareholder value.

Discover why KENVEU’s new TYLENOL® with Naproxen is a first‑mover game‑changer in OTC pain relief—rapid, single‑dose, dual‑action analgesia with a three‑year exclusivity advantage.

FDA approves Kenvue’s Tylenol® with Naproxen, a fast‑acting, 12‑hour, opioid‑free OTC pain reliever combining acetaminophen and naproxen in one dose.

McCormick’s new global flavor powerhouse unites Unilever Foods, unlocking $2.3 billion in synergies, a Dutch HQ, and dual‑listing growth for investors.

Unilever exits Venezuela’s ice‑cream market, letting Grupo Nutresa expand exports and build supply‑chain resilience—showing Latin America’s shift to regional growth.

Gabriel India’s Q1 FY 2026‑27 shows 8.4 % revenue growth, 12.7 % EBIT rise and a 12.4 % EPS boost as acquisitions in HL Mando Anand and HL Klemove India pivot it to high‑margin chassis and ADAS segments, positioning the company for future‑proof mobi…

Unilever’s food business sale to McCormick now under CMA review—discover the competitive risks, potential market shifts and financial implications for UK consumers and investors.

Clorox EVP/COO sells a small stake per Form 4, showing routine insider trading, tax withholding, and DRIP buys—insightful for investors and regulators alike.

Stockholm market sees mixed earnings, with defence and logistics firms topping forecasts while hygiene products face cost pressures and investor scrutiny.

PG’s latest quarterly report shows steady core revenue, smart cost cuts, and focused innovation—insights into how Procter & Gamble stays profitable and resilient amid shifting consumer demand.